RESEARCH TRIANGLE PARK, NC – April 23, 2012 – Quintiles, the world’s leading global biopharmaceutical services company, today announced the appointment of Tom Pike as chief executive officer. This appointment is part of the company’s long-term succession planning. Dennis Gillings, CBE, who founded the company, continues as executive chairman of its Board of Directors. Pike joins Quintiles on April 30, 2012.
Tom has an impressive track record of helping customers navigate fast-changing environments and solving complex business issues,” Gillings said. “He has experience with organizations our size and much larger that will be extremely valuable to us. Tom has a disciplined and forthright approach that will enable him to earn the trust of customers and employees alike. I’m confident he will soon make his mark on our company and the industry at large, continuing the Quintiles tradition of entrepreneurial leadership and pioneering growth.”
Pike brings 30 years of experience to Quintiles, spanning a variety of industries and leading companies. He spent 22 years at Accenture, including more than 10 years in leadership roles. At Accenture, Pike’s roles included leading the North America Health and Products business areas. Prior to that, he was the global chief operating officer for Accenture’s Resources operating group and had also served as the company’s chief strategy officer. Since leaving Accenture in 2010, Pike has been involved with a number of start-ups in the technology and healthcare sectors.
Pike said: “Healthcare is the most important industry of the next quarter century, and I’m excited because Quintiles is right at the center of improving the health of millions of people around the world. It’s extremely motivating to join the company at this point in time. I understand the magnitude and complexity of its customers’ challenges. I’m looking forward to bringing my skills and experience to help this talented team build on its successes as it continues its journey as one of the world’s great companies.”
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. Our network of more than 25,000 professionals in 60 countries has an eye on the future while delivering results today with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies develop and commercialize products to improve and lengthen patients’ lives while demonstrating value to stakeholders. Visit www.quintiles.com for more information and www.quintiles.com/news for additional company news.